Alzheimer's is often associated as a neurological problem that robs away one's memory. Researchers across the globe have been trying to find effective treatments for the same. However, it seems that they have been getting closer to get a novel and result assuring drug.

Recently, a study was being presented in Boston, which revealed that the drug Solanezumab is able to reduce the mental decline among patients, who are at initial stage of Alzheimer's. There was a generous decline of 34% among patients.

Study researchers at the American Neurological Association meeting were of the view that they are quite satisfied with the result, but they would like to carry out further research on the matter. Further research will help them to get assured about the drug.

"I think the question has been answered favorably, especially on cognition and perhaps activities of daily living in patients with milder", asserted Dr. Rachelle Doody, who led the panel, which assessed the drug being developed by Eli Lilly.

In order to know the efficacy of the drug, an experiment was being taken out on 2,000 patients. The drug was continuously given for 18 months and improvements were being seen among patients in comparison to those, who took placebo.